PMID- 32424494
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1307
DP  - 2021
TI  - Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
PG  - 417-440
LID - 10.1007/5584_2020_532 [doi]
AB  - Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading liver disease 
      globally. NAFLD patients can have a progressive phenotype, non-alcoholic 
      steatohepatitis (NASH) that could lead to cirrhosis, liver failure and cancer. 
      There is a close bi-directional relationship between NAFLD and type 2 diabetes 
      mellitus (T2DM); NAFLD increases the risk for T2DM and its complications whereas 
      T2DM increases the severity of NAFLD and its complications. The large global 
      impact of NAFLD and T2DM on healthcare systems requires a paradigm shift from 
      specialty care to early identification and risk stratification of NAFLD in 
      primary care and diabetes clinics. Approach to diagnosis, risk stratification and 
      management of NAFLD is discussed. In addition to optimizing the control of 
      coexisting cardiometabolic comorbidities, early referral of NAFLD patients at 
      high risk of having NASH or significant fibrosis to hepatology specialist care 
      may improve management and allow access for clinical trials. Lifestyle 
      modifications, vitamin E, pioglitazone and metformin are currently available 
      options that may benefit patients with T2DM and NAFLD. The burst of clinical 
      trials investigating newer therapeutic agents for NAFLD and NASH offer hope for 
      new, effective and safe therapies in the near future.
FAU - Khneizer, Gebran
AU  - Khneizer G
AD  - Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, 
      USA.
FAU - Rizvi, Syed
AU  - Rizvi S
AD  - A&M College of Medicine, Round Rock, Austin, TX, USA.
FAU - Gawrieh, Samer
AU  - Gawrieh S
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Indiana 
      University School of Medicine, Indianapolis, IN, USA. sgawrieh@iu.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Humans
MH  - Liver Cirrhosis
MH  - Metformin/therapeutic use
MH  - *Non-alcoholic Fatty Liver Disease/diagnosis/epidemiology/therapy
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - GLP1
OT  - Metformin
OT  - NAFLD
OT  - NASH
OT  - Pioglitazone
OT  - SGLT2
OT  - vitamin E
EDAT- 2020/05/20 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1007/5584_2020_532 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2021;1307:417-440. doi: 10.1007/5584_2020_532.